Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly's 3Q Revenues up 20% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Lilly’s 3Q Revenues up 20%

Growth in the quarter driven by Mounjaro and Zepbound sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
3Q Revenues: $11.4 billion (+20%) 
3Q Earnings: $970.3 million (loss of $57.4 million 3Q23) 
YTD Revenues: $31.5 billion (+27%)
YTD Earnings: $6.2 billion (+103%)
Comments: Mounjaro sales were $3.1 billion in the quarter, up from $1.4 billion 3Q23. Verzenio sales were up 32% to $1.37 billion. Zepbound sales were $1.26 billion in the quarter. Trulicity sales were down 22% in the quarter to $1.3 billion. 
 
Revenue in the U.S. increased 46% to $7.8 billion, driven by a 35% increase in volume and an 11% increase in realized prices. The increase in U.S. volume was driven by Zepbound and Mounjaro, partially offset by declines in Trulicity. 
 
Revenue outside the U.S. decreased 12% to $3.63 billion driven by the sale of rights for the olanzapine portfolio in 3Q23. Excluding the olanzapine portfolio, revenue and volume outside the U.S. increased 33% and 36%, respectively, primarily driven by Mounjaro and Verzenio.
Approvals in the quarter included Ebglyss in the U.S. for moderate-to-severe atopic dermatitis and Kisunla in Japan for early symptomatic Alzheimer’s disease.
 
3Q23 results include $2.98 billion charges primarily related to the acquisitions of DICE Therapeutics, Inc., Versanis Bio, Inc. and Emergence Therapeutics AG.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters